SCHEMBL1440263

SCHEMBL1440263

N=C(N)Nc1c(Cl)cccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.43
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
GAA P10253 1/20 0.42
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
TAAR1 Q96RJ0 2/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
PTPN7 P35236 1/20 0.39
DUSP3 P51452 1/20 0.39
PTPN5 P54829 1/20 0.39
PTPN11 Q06124 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PLAU P00749 1/20 0.38
PLAT P00750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11050009 0.98 TYK2 (0.42) TYK2LMNAMEN1KMT2AGAA
SCHEMBL11884423 0.86 BACE1 (0.46) TYK2KMT2AGAAPDK1PDK2
SCHEMBL11879361 0.86 GAA (0.37) TYK2LMNAMEN1KMT2AGAA
SCHEMBL11883002 0.86 GAA (0.37) TYK2LMNAMEN1KMT2AGAA
SCHEMBL11497911 0.86 PDK1 (0.46) TYK2LMNAMEN1KMT2AGAA
SCHEMBL4206477 0.84 TYK2 (0.39) TYK2LMNAMEN1KMT2AGAA
SCHEMBL11884358 0.83 L3MBTL1 (0.47) TYK2LMNAPDK1PDK2PDK3
Hydrochloric Acid SCHEMBL16701798 0.82 TYK2 (0.38) TYK2LMNAMEN1KMT2AGAA
SCHEMBL11057728 0.81 CYP1A2 (0.49) TYK2LMNAMEN1KMT2APDK1
SCHEMBL11074940 0.81 GAA (0.50) LMNAMEN1KMT2AGAATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0008150-B1 2,6-DICHLOROPHENYL-SUBSTITUTED AMINO-IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARING SUCH DERIVATIVES AND PHARMACEUTICAL PREPARATIONS COMPRISING SAID DERIVATIVES Farmos-Yhtyma Oy (FI) 1982-04-28 EP claimed
EP-0008150-A2 2,6-Dichlorophenyl-substituted amino-imidazole derivatives, processes of preparing such derivatives and pharmaceutical preparations comprising said derivatives Farmos-Yhtyma Oy (FI) 1980-02-20 EP claimed
US-12006294-B2 Therapeutic compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-06-11 US disclosed
US-20190330157-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2019-10-31 US disclosed
US-20190330157-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2019-10-31 US disclosed
US-9765020-B2 Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis CELLIX BIO PRIVATE LIMITED (IN) 2017-09-19 US disclosed
US-9765020-B2 Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis CELLIX BIO PRIVATE LIMITED (IN) 2017-09-19 US disclosed
US-9765020-B2 Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis CELLIX BIO PRIVATE LIMITED (IN) 2017-09-19 US disclosed
US-20150307446-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS CELLIX BIO PRIVATE LIMITED (IN) 2015-10-29 US disclosed
US-20150307446-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS CELLIX BIO PRIVATE LIMITED (IN) 2015-10-29 US disclosed
US-20150307446-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS CELLIX BIO PRIVATE LIMITED (IN) 2015-10-29 US disclosed
WO-2011029046-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2011-03-10 WO disclosed
EP-0405525-A2 Novel cyanoguanidine derivatives KANEBO, LTD. (JP) 1991-01-02 EP disclosed
US-4488993-A Amidinoureas WILLIAM H. RORER, INC. 1984-12-18 US disclosed
EP-0008150-B1 2,6-DICHLOROPHENYL-SUBSTITUTED AMINO-IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARING SUCH DERIVATIVES AND PHARMACEUTICAL PREPARATIONS COMPRISING SAID DERIVATIVES Farmos-Yhtyma Oy (FI) 1982-04-28 EP disclosed
US-4275072-A 2,6-Dichlorophenyl-substituted amino-imidazole derivatives and use as hypertensive agents FARMOS GROUP, LTD. (FI) 1981-06-23 US disclosed
US-4220658-A Treatment of hypertension with amidinoureas WILLIAM H. RORER, INC. (US) 1980-09-02 US disclosed
EP-0008150-A2 2,6-Dichlorophenyl-substituted amino-imidazole derivatives, processes of preparing such derivatives and pharmaceutical preparations comprising said derivatives Farmos-Yhtyma Oy (FI) 1980-02-20 EP disclosed
US-4088785-A HYPOTENSIVE AGENTS WILLIAM H. RORER, INC. (US) 1978-05-09 US disclosed
US-3976643-A FROM AN ANILINE AND CYANAMIDE WILLIAM H. RORER, INC. (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330157-A1 THERAPEUTIC COMPOUNDS OPRL1, INA, OGFR TYK2 3643/4885LMNA 1901/4885MEN1 4058/4885
US-12006294-B2 Therapeutic compounds OPRL1, INA, OGFR TYK2 3643/4885LMNA 1901/4885MEN1 4058/4885
US-20150307446-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS MUC1, SI, ALPI TYK2 3511/4885LMNA 3373/4885MEN1 4063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.